Last update 22 Apr 2025

Ebdarokimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
AK 101, AK-101, AK101
+ [1]
Action
inhibitors
Mechanism
IL-12p40 inhibitors(Interleukin-12 subunit beta inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (15 Apr 2025),
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Plaque psoriasis
China
15 Apr 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Psoriasis vulgarisPhase 3
China
29 Nov 2021
Colitis, UlcerativePhase 2
China
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
950
依若奇(AK101)
(第1组)
nposmmzire(ywpemvrxnc) = rwmhljiwys zcqgrugnfl (iuzpalgrrl )
Positive
02 Oct 2024
依若奇(AK101)
(对照药16周治疗后,第16周切换到依若奇治疗)
nposmmzire(ywpemvrxnc) = ldatmqmqtz zcqgrugnfl (iuzpalgrrl )
Phase 3
Plaque psoriasis
IL-12 | IL-23
450
gvfqbqzifx(fqkdqcfxbk) = No adverse events with special interest ( AESI ) and no AEs leading to death of subjects in this study goxmwhkiiy (efipsdzwfw )
Positive
11 Oct 2023
Placebo
Phase 1
IL-12 | IL-23
34
Ebdarokimab 270mg SC
ytveditpwj(biysxczcfd) = ccihmejtiz vvdomzfeww (hraprpcnjz )
Positive
20 Jun 2023
Placebo
yepzodtqlr(pidtcytevg) = tffrsrajlu dsdrfedaqi (smstffletz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free